Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2022

BioSenic appoints Michel Wurm, M.D. as Chief Medical Officer

  • Read more about BioSenic appoints Michel Wurm, M.D. as Chief Medical Officer

Information on the total number of voting rights and shares

  • Read more about Information on the total number of voting rights and shares

CAP INNOV EST

  • Read more about CAP INNOV EST

François Rieger

  • Read more about François Rieger

FA DIESE

  • Read more about FA DIESE

CPH

  • Read more about CPH

Veronique Pomi

  • Read more about Veronique Pomi

Transparency notifications received from François Rieger, Véronique Pomi, Capital Grand Est, FA DIESE 3 and CPH Banque

  • Read more about Transparency notifications received from François Rieger, Véronique Pomi, Capital Grand Est, FA DIESE 3 and CPH Banque

BioSenic provides update on its autoimmune disease platform based on ATO (arsenic trioxide)

  • Read more about BioSenic provides update on its autoimmune disease platform based on ATO (arsenic trioxide)

Transparency notification received from S.R.I.W. SA and Sofipôle SA

  • Read more about Transparency notification received from S.R.I.W. SA and Sofipôle SA

Pagination

  • Next page ››
Subscribe to 2022
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions